Secondary Logo

Journal Logo

Hepatitis B Vaccination and Infection Prevalence Among Men Who Have Sex With Men Who Travel Internationally

Truong, Hong-Ha, M., PhD, MS, MPH*†; Fatch, Robin, MPH*; Do, Tri, D., MD, MPH*‡; McFarland, Willi, MD, PhD

Sexually Transmitted Diseases: May 2018 - Volume 45 - Issue 5 - p e25–e28
doi: 10.1097/OLQ.0000000000000743

Among men who have sex with men traveling internationally, self-reported hepatitis B virus (HBV) vaccination prevalence was 77% and less prevalent among older men and those with HBV infection. The HBV infection prevalence was 25% and was associated with older age and HIV infection. Testing for chronic infection, universal vaccination, and treatment for populations with multiple risks is needed.

Hepatitis B virus vaccination coverage is still not universal among men who have sex with men. Vigorous testing for hepatitis B virus infection, universal vaccination, and treatment for populations with multiple risks for infection is needed.

From the *University of California; †Gladstone Institutes; ‡Asian & Pacific Islander Wellness Center; and §Department of Public Health, San Francisco, 94102, USA

Funding: NIH R01 MH 080657 (PI: Hong-Ha M. Truong), NIH R01 MH 080657-03S1 (PI: Hong-Ha M. Truong).

Conflicts of Interest: None declared.

Correspondence: Hong-Ha M. Truong, PhD, MD, MPH, Department of Medicine, University of California, San Francisco, 3rd Flr, 550 16th St., San Francisco, CA 94158. E-mail:

Received for publication April 10, 2017, and accepted October 3, 2017.

The 2017 to 2020 National Viral Hepatitis Action Plan (NVHAP) calls for the elimination of new viral hepatitis infections, screening for persons at risk, and access to care and treatment for persons living with chronic infections.1 National Viral Hepatitis Action Plan cites low public awareness, low perceived risk, and limited data to monitor infections as critical barriers to stemming the spread of viral hepatitis.1

Hepatitis B virus (HBV), a bloodborne and sexually transmitted infection, is a major etiology of liver disease.1,2 In the United States and other countries with low endemicity, the primary exposure routes are sexual contact and injection drug use.2 Centers for Disease Control and Prevention estimates 850,000 Americans are living with HBV, though other studies suggest the actual numbers may exceed 2 million.3,4

International travelers can be susceptible to infection, especially when visiting HBV-endemic regions. Travelers often are unaware of travel-related HBV risk factors, such as condomless sex, injection drug use, and medical/dental care while abroad.5,6 A study of US travelers to HBV-endemic areas found that 32% of the travelers reported a travel-related risk; and 31% sought travel medical advice before departure, of whom fewer than one third were vaccinated, thus placing them at potential risk for infection.5

An HBV vaccine was shown to be safe and effective in a randomized controlled trial that included men who have sex with men (MSM) known to be at high risk for infection.7 The HBV vaccination recommendations first issued in 1982 specified targeted vaccination of adults at risk for infection, including MSM, persons who inject drugs and international travelers.8 Despite these longstanding recommendations, in 2014, only an estimated 24.5% of adults in the United States had been vaccinated, indicating missed opportunities for high-risk adult populations, particularly MSM.9

MSM continue to be disproportionately affected, accounting for 24% of new infections.2 They are at elevated risk due to high prevalence of HBV among MSM populations and increased transmission risk associated with condomless anal intercourse.2,10 International travel could expose MSM to even higher prevalence populations. We therefore assessed HBV vaccination and infection in a community-based sample of MSM who travel internationally.

MSM were recruited using an adapted respondent-driven sampling method between 2009 and 2011. A detailed description of recruitment procedures has been previously reported.11 Eligible MSM were San Francisco Bay Area residents who were 18 years or older, and traveled internationally in the previous 12 months. Of the original 501 participants enrolled in the study, 478 with blood specimens available for HBV testing were included in this analysis. The study received approval from the institutional review board at the University of California, San Francisco.

Participants completed an interviewer-administered, computer-assisted survey. Demographic characteristics collected included age, race, ethnicity, education, and birth country. Participants were asked about the two most recent countries they visited in the previous 12 months. Hepatitis B virus vaccination was self-reported. HBV infection was defined as a positive result by total anti–hepatitis B core (HBc) serological testing (ADVIA Centaur HBC Total assay; Siemens Healthcare Diagnostics Inc., Tarrytown, NY). A positive HBc test result does not provide information on stage of infection, for example, acute, chronic, or cleared. Birth and visited countries were classified as HBV-endemic if the national prevalence of HBV surface antigen in that country was 8% or higher.12 The HIV status was determined by rapid antibody serological testing.

Frequency distributions were calculated for categorical variables. Medians and interquartile ranges were calculated for continuous variables. Prevalence ratios (PRs) were estimated for the outcomes of HBV vaccination and infection. Bivariate and multivariable Poisson regression models with robust errors calculated PRs, adjusted PRs (aPRs), and 95% confidence intervals (CIs). Variables associated at P values less than 0.20 in bivariate analyses were included in multivariable analyses.

Self-reported HBV vaccination prevalence was 77% overall and was highest among men ages 18 to 40 years (86%), decreasing significantly with every 10-year increase in age (aPR = 0.95; P = 0.04), as presented in Table 1. HBV-infected men (positive for total HBc) were less likely to report vaccination (aPR = 0.60; P < 0.01). Fifty-eight of the 117 men with HBV infection (50%) reported being vaccinated.



The HBV infection prevalence was 25% overall and was higher among older men, increasing significantly with every 10-year increase in age (aPR = 1.49; P < 0.01), as shown in Table 2. The HIV-positive men were more likely to be infected (aPR = 2.43, P < 0.01), whereas vaccinated men were less likely to be infected (aPR = 0.46, P < 0.01). Although race/ethnicity was not significantly associated with HBV infection (P = 0.09), black men were at elevated risk (aPR = 2.22; 95% CI: 1.20, 4.10) compared with white men.



Persons who travelled to an HBV-endemic country in the previous 12 months were slightly more likely to report vaccination (82% vs 76%; PR = 1.09; P = 0.08) and less likely to be infected (21% vs 26%; PR = 0.82; P = 0.31). Persons born in an HBV-endemic country were slightly more likely to report vaccination (86% vs 77%; PR = 1.12; P = 0.10) and less likely to be infected (19% vs 25%; PR = 0.76 P = 0.41).

MSM, particularly those who travel internationally, continue to be at high risk for HBV infection. Nearly one quarter of the men in our study reported not being vaccinated. Self-reported vaccination prevalence was lowest among men older than 50 years. This finding may be due in part to the fact that national guidelines recommending universal HBV vaccination for infants and children were not updated until the 1990s, and therefore would not have affected older individuals.13,14 One third of HIV-positive men reported not being vaccinated for HBV, a worrisome finding as studies on the timing of HBV vaccination relative to HIV diagnosis and the persistent rate of HBV infection post-HIV diagnosis suggest completing the vaccine series before HIV infection may be the best strategy for preventing HIV-HBV comorbidity.15 Centers for Disease Control and Prevention projects have demonstrated the feasibility of integrating HBV prevention services in a variety of settings, including sexually transmitted infection clinics, HIV testing sites, and correctional facilities, which may present an opportunity to reach unvaccinated older MSM.16

One quarter of participants tested positive for total HBc. The HBV infection prevalence was highest among men who were black, older, or HIV-positive. By virtue of their age, older men had more time to acquire HBV infection. A somewhat unexpected finding was that being born in an HBV-endemic country was not associated with infection. Previous studies found foreign-born persons were 9.2 times more likely to have chronic HBV compared with US-born individuals.17 The length of time that non–US-born men lived in their birth countries before migration to the United States may have affected our results, since persons immigrating at a younger age may have a similar infection risk as those born in the United States. Alternatively, increased prevalence of HBV infection among older MSM may have reduced differences in country of origin over time.

Prevalence of HBV vaccination and infection in this study population was higher than previous data among MSM in other US cities. In Los Angeles County, 46% of MSM participating in the National HIV Behavioral Surveillance system were vaccinated, and 19% had serologic evidence of current or past infection.12 Other studies reported vaccination prevalence ranging from 9% to 42% and serological evidence of infection ranging from 11% to 20%.18,19 Our study population was comprised of MSM who travel internationally, which may account for the higher prevalence of HBV vaccination and infection observed. Our participants may have been at higher risk for HBV infection as a result of their international travel. As previously reported, 25% of our participants reported engaging in condomless anal intercourse while traveling internationally.20 Study participants also may have been more aware of the potential risk for acquiring HBV as a result of their sexual activity or travel destinations and thus sought vaccination.

The study did not assess participants' reasons for their HBV vaccination decisions. Among participants who reported being vaccinated, timing of the vaccination relative to international travel or HIV diagnosis was not collected. Our study also could not determine if infection occurred in childhood, as an adult in the United States, or after international travel. Moreover, serological testing for this study assessed HBV infection in the absence of testing for immunity; therefore, acute and chronic HBV infection would not be detected.

The HBV vaccination coverage is still not universal among MSM, even though they remain at high risk for infection. Men who have sex with men were a priority population for vaccination programs in the first national vaccination recommendations released in 1982 and are still considered a priority population in the NVHAP for 2017 to 2020.1 Older men, in particular, have not fully benefited from the availability of a safe and effective vaccine. This public health gap is particularly distressing considering that it was this generation of older MSM who participated in the HBV vaccination efficacy trials. We identified a high proportion of HBV-infected individuals who reported vaccination, some of whom may have been chronically infected. In the absence of screening for active infection, vaccinated individuals may have a false sense of protection and may not be identified for treatment. This finding highlights the importance of screening for HBV infection with appropriate testing before vaccination, because vaccination does not confer benefit to chronically infected individuals.

Our study highlights the critical need for vigorous testing for HBV infection, including chronic infection, universal vaccination, and treatment where needed for populations with multiple risks for infection. The Affordable Care Act has expanded access to health insurance for many Americans.21–23 Increased coverage for the preventive services of HBV screening and vaccination will help achieve NVHAP’s goal of universal HBV vaccination for vulnerable adults.

Back to Top | Article Outline


1. Department of Health and Human Services. National Viral Hepatitis Action Plan 2017–2020. Available at:
2. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16):1–33.
3. U.S. Centers for Disease Control and Prevention, Division of Hepatitis. Viral hepatitis surveillance United States, 2014. Available at:
4. Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012; 56:422–433.
5. Connor BA, Jacobs RJ, Meyerhoff AS. Hepatitis B risks and immunization coverage among American travelers. J Travel Med 2006; 13:273–280.
6. Zuckerman JN, Hoet B. Hepatitis B immunisation in travellers: poor risk perception and inadequate protection. Travel Med Infect Dis 2008; 6:315–320.
7. Szmuness W, Stevens CE, Harley EJ. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833–841.
8. Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. MMWR 1982; 31:317–322, 327–328.
9. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2014. MMWR Surveill Summ 2016; 65:1–36.
10. Pitasi M, Bingham TA, Sey EK, et al. Hepatitis B Virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County, USA. AIDS Behav 2014; 18 Suppl 3:248–255.
11. Truong HM, Grasso M, Chen YH, et al. Balancing theory and practice in respondent-driven sampling: a case study of innovations developed to overcome recruitment challenges. PLoS One 2013; 8:e370344.
13. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40(RR-13):1–25.
14. Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission-United States. MMWR 1999; 48:33–34.
15. Landrum ML, Hullsiek KH, Chun HM, et al. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol 2011; 173:84–93.
16. Integrating viral hepatitis prevention into public health settings. Public Health Rep 2007; 122(Suppl 2):1–101.
17. Liu SJ, Iqbal K, Shallow S, et al. Characterization of chronic hepatitis B cases among foreign-born persons in six population-based surveillance sites, United States 2001–2010. J Immigr Minor Health 2015; 17:7–12.
18. Reiter PL, Brewer NT. Hepatitis B vaccination among a national sample of gay and bisexual men. Sex Transm Dis 2001; 38:235–238.
19. MacKellar DA, Valleroy LA, Secura GM, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001; 91:965–971.
20. Truong HM, Fatch R, Grasso M, et al. Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco. Sex Transm Infect 2015; 91:220–225.
21. Roundtable on Population Health Improvement; Board on Population Health and Public Health Practice; Institute of Medicine. Population health implications of the Affordable Care Act: workshop summary. Washington (DC): National Academies Press (US), 2014.
22. Kominski GF, Nonzee NJ, Sorensen A. The Affordable Care Act’s impacts on access to insurance and health care for low-income populations. Annu Rev Public Health 2017; 38:489–505.
23. Simon K, Soni A, Cawley J. The impact of health insurance on preventive care and health behaviors: evidence from the first two years of the ACA Medicaid expansions. J Policy Anal Manage 2017; 36:390–417.
© Copyright 2018 American Sexually Transmitted Diseases Association